UPDATE: Sequenom, GSK Team to Create SNP Assay Portfolio | GenomeWeb

NEW YORK, Aug. 29 – Sequenom has begun the first phase of a research partnership with British drug giant GlaxoSmithKline to create a human genome-wide SNP assay portfolio to help them identify genes responsible for disease states and drug reaction, the companies said on Wednesday.

The deal calls for GlaxoSmithKline to be given access to Sequenom’s SNP assay portfolio. The pharmaceutical company then plans to select SNP candidates for genome-wide association studies. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.